Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.00232
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

Oncologist
Cancer ResearchMedicineOncology
2013English

Optimizing Combination Dabrafenib and Trametinib Therapy in BRAF Mutation-Positive Advanced Melanoma Patients: Guidelines From Australian Melanoma Medical Oncologists

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2016English

Improved Overall Survival in Melanoma With Combined Dabrafenib and Trametinib

New England Journal of Medicine
Medicine
2015English

BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade With Dabrafenib, Trametinib, and Panitumumab in Patients With Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2020English

Redifferentiation of Iodine-Refractory BRAF V600e-Mutant Metastatic Papillary Thyroid Cancer With Dabrafenib

Clinical Cancer Research
Cancer ResearchOncology
2014English

Detection of Mutant BRAF Alleles in the Plasma of Patients With Metastatic Melanoma

Journal of Molecular Diagnostics
Forensic MedicinePathologyMolecular Medicine
2007English

Granulomatosis With Polyangiitis in a Patient Treated With Dabrafenib and Trametinib for BRAF V600E Positive Lung Adenocarcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

PCN87 Cost Effectiveness Evaluation of Vemurafenib, an Orphan Drug for Braf Mutant Metastatic Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

A Murine Model for Metastatic Conjunctival Melanoma

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy